An ozone composition, its preparation and use

Abstract

This invention provides an ozone composition, its preparation method, and its application, belonging to the field of pharmaceutical technology. The invention provides an ozone composition comprising a polymer containing ether bonds and / or hydroxyl groups and ozone dissolved in the polymer. This invention uses a polymer containing ether bonds and / or hydroxyl groups as a carrier. Through its flexible molecular chain and polar environment, it encapsulates, slows down the release of, and stabilizes ozone molecules, enabling ozone to dissolve more efficiently and remain stable. This enhances ozone solubility and significantly improves ozone stability, preventing ozone volatilization loss.

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical technology, specifically relating to an ozone composition, its preparation method, and its application. Background Technology

[0002] Ozone (O3) is a strong oxidant widely used in disinfection, air purification, water treatment, and medical treatment. In cancer treatment, ozone is believed to have anti-tumor effects due to its unique oxidizing properties. Ozone can induce tumor cell death and immune activation by oxidizing the membrane lipids, proteins, and nucleic acids of tumor cells. In recent years, the application of ozone in cancer treatment has received increasing attention, especially its potential to improve the effectiveness of chemotherapy and reduce side effects.

[0003] Currently, the application of ozone in therapy mainly relies on the direct use of ozone gas or the use of ozone water. However, as an unstable molecule, ozone's solubility and stability in water are significantly limited. Ozone's solubility in water is low, approximately 0.08–0.13 g / L, and it decomposes readily at room temperature, greatly affecting its therapeutic efficacy during storage and use. To overcome these problems, researchers have tried various methods to improve ozone's solubility and stability, such as adjusting pH and using chemical reagents like peroxides. However, these methods often fail to address the rapid degradation of ozone in aqueous solutions, and controlling ozone concentration remains challenging. Therefore, improving ozone's solubility and stability has become a pressing technical challenge in this field. Summary of the Invention

[0004] The purpose of this invention is to provide an ozone composition, its preparation method, and its application. The ozone composition provided by this invention can improve the solubility and stability of ozone.

[0005] To achieve the above-mentioned objectives, the present invention provides the following technical solution: The present invention provides an ozone composition comprising a polymer containing ether bonds and / or hydroxyl groups and ozone dissolved in said polymer.

[0006] Preferably, the concentration of ozone in the ozone composition is 0.1~200g / L.

[0007] Preferably, the ozone composition is in the form of a liquid, a semi-solid, or a solid.

[0008] The present invention also provides a method for preparing the ozone composition described in the above technical solution, comprising: Ozone is dissolved by passing it into a polymer containing ether bonds and / or hydroxyl groups to obtain an ozone composition.

[0009] The present invention also provides the application of the ozone composition described in the above technical solution or the ozone composition prepared by the preparation method described in the above technical solution in antitumor drugs, anti-infective drugs or immunomodulators.

[0010] Preferably, the application includes: use alone or as a sensitizer for chemotherapy, radiotherapy, immunotherapy, targeted therapy or oncolytic virus therapy.

[0011] This invention provides an ozone composition comprising a polymer containing ether bonds and / or hydroxyl groups and ozone dissolved in said polymer. The ether bonds and polar groups (hydroxyl groups) in the polymer used in this invention provide a stable dissolution environment for ozone, thereby improving the solubility and stability of ozone. Results from the examples show that the ozone composition provided by this invention maintains an ozone content of 90.23% for one month and 79.65% for six months at a low temperature of -20°C.

[0012] This invention uses low molecular weight polyethylene glycol as a carrier. Through its flexible molecular chain and polar environment, it can encapsulate, slow-release, and stabilize ozone molecules, enabling ozone to dissolve more efficiently and exist stably. This enhances the solubility of ozone and significantly improves its stability, thus avoiding the loss of ozone through volatilization. Attached Figure Description

[0013] Figure 1 The absorbance curves are for the ozone composition of Example 1 and PEG-200 of Comparative Example 1. Figure 2 Stability curves of the ozone composition prepared in Example 2 and the ozone aqueous solution in Comparative Example 2 at room temperature; Figure 3 Gross observations of mice after injection of subcutaneous tumors in the PBS group, HCl 6.0 group, HCl 5.0 group, PEG200 group, PEG200-O3 1g / L group and PEG200-O3 6g / L group, respectively; Figure 4 The tumor volume curves before and after injection of subcutaneous tumors in mice were obtained using PBS, HCl 6.0, HCl 5.0, PEG200, PEG200-O3 1g / L, and PEG200-O3 6g / L groups, respectively. Figure 5 This is a scatter plot summarizing the weight of subcutaneous tumors in mice obtained from dissection after two intratumoral administrations. Detailed Implementation

[0014] The present invention provides an ozone composition comprising a polymer containing ether bonds and / or hydroxyl groups and ozone dissolved in said polymer.

[0015] The ozone composition provided by this invention comprises a polymer; the polymer preferably comprises polyethylene glycol; the average molecular weight of the polyethylene glycol is preferably 100-2000, more preferably 100-1000. This invention uses low molecular weight polyethylene glycol as a carrier, which, through its flexible molecular chains and polar environment, encapsulates, slows release, and stabilizes ozone molecules, enabling ozone to dissolve more efficiently and exist stably, enhancing ozone solubility, significantly improving ozone stability, and avoiding ozone volatilization loss. In contrast, high molecular weight polyethylene glycol hinders molecular movement and cannot effectively encapsulate ozone molecules. Compared to the complex components of existing carriers, this invention further reduces costs, improves ozone solubility and stability, and is also beneficial for subsequent intratumoral injection.

[0016] In this invention, the polyethylene glycol preferably includes at least one of polyethylene glycol-200 (PEG-200), polyethylene glycol-400 (PEG-400), polyethylene glycol-800 (PEG-800), and polyethylene glycol-1000 (PEG-1000).

[0017] The repeating structural unit of polyethylene glycol in the ozone composition provided by this invention can be represented as: HO-(CH2CH2O) n -H, where n is an integer; The ether bonds and polar groups (hydroxyl groups) in the polyethylene glycol molecular chain provide a stable dissolution environment for ozone. Ozone does not form covalent bonds with polyethylene glycol, but exists stably through physical dissolution and intermolecular forces, thus maintaining the high reactivity of ozone.

[0018] The ozone composition provided by the present invention further includes ozone dissolved in the polyethylene glycol; the concentration of ozone in the ozone composition is preferably 0.1~200 g / L. In one embodiment, the concentration of ozone in the ozone composition can be 2 g / L, 3 g / L, 4 g / L, 5 g / L, 6 g / L, 7 g / L, 8 g / L, 9 g / L, 10 g / L, 20 g / L, 30 g / L, 40 g / L, 50 g / L, 60 g / L, 70 g / L, 80 g / L, 85 g / L, 90 g / L, 95 g / L, 100 g / L, 105 g / L, 110 g / L, 115 g / L, 120 g / L, 125 g / L, 130 g / L, 135 g / L, 140 g / L, 145 g / L, 150 g / L, 160 g / L, 170 g / L, 180 g / L, or 190 g / L.

[0019] In this invention, the ozone composition is preferably in the form of a liquid, a semi-solid, or a solid.

[0020] The ozone composition of this invention has significant advantages over existing technologies. The ozone composition exhibits high purity: by using polyethylene glycol as a carrier, ozone can dissolve and remain stable more efficiently, resulting in an ozone composition with high purity and yield. Polyethylene glycol not only enhances the solubility of ozone but also significantly improves its stability, effectively preventing rapid volatilization or decomposition, maintaining its activity, ensuring the purity and effectiveness of the final product, and avoiding ozone loss through volatilization. This technological advantage allows the ozone composition of this invention to maintain high activity and efficacy during application, meeting precise treatment needs.

[0021] The ozone composition provided by the present invention uses polyethylene glycol as a carrier and is formed by introducing and stably loading ozone into the polyethylene glycol system; the ozone composition is a liquid system that can exist stably at high concentrations and is suitable for biomedical applications such as anti-tumor therapy.

[0022] Compared with existing ozone water or ozone gas, the ozone composition of the present invention has significant advantages such as high ozone concentration, good stability and long storage time.

[0023] In the ozone composition provided by this invention, polyethylene glycol serves as a dissolving carrier and stabilizing matrix for ozone, providing an environment for ozone dispersion and stable existence. Ozone, as an active ingredient, is loaded and dissolved in the polyethylene glycol system. Based on the total volume of the ozone composition, the ozone content is 0.1~200 g / L, polyethylene glycol is the continuous phase, and ozone exists in polyethylene glycol in a dissolved and dispersed form.

[0024] The ozone composition provided by this invention does not belong to the structure type of a single small molecule compound, but to a carrier-active component type system. Its structural characteristics can be described as follows: the carrier is polyethylene glycol, and the active component is ozone. The structural form is that ozone is dissolved in molecular state and exists stably in the liquid phase system formed by polyethylene glycol. This structure is similar to a "dissolved-loaded structure".

[0025] The physical parameters of the ozone composition provided by this invention are as follows: 1. Appearance: Colorless or light-colored transparent liquid; 2. State: Liquid at -20~25℃; 3. Ozone concentration: 0.1~200g / L; 4. Stability: Under sealed storage conditions at -20℃, the ozone content remains above 90% after 1 month and above 78% after 2 months; 5. pH characteristics: The pH value decreases as the ozone concentration increases; the pH value of the ozone composition is 6.0 when the ozone concentration is 1 g / L; the pH value of the ozone composition is 5.0 when the ozone concentration is 6 g / L. 6. Volatility: Significantly lower than ozone water and ozone gas.

[0026] The ozone composition of the present invention uses polyethylene glycol as a carrier to stabilize high-concentration ozone, forming a functional product with a well-defined structure, clear composition, and controllable physical properties. Its essential characteristics are: ozone exists in the form of active molecules, and polyethylene glycol provides a stable dissolution and sustained-release environment. It belongs to a highly stable, high-concentration ozone loading system, which provides a reliable material basis for subsequent applications in biomedical fields such as anti-tumor therapy.

[0027] The ozone composition of this invention can achieve an ozone concentration of 1 g / L in 3 hours and a stable concentration of 6 g / L in 17 hours. This is significantly higher than the ozone concentration generated by existing ozone solutions in the same time period, solving the problem of limited ozone solubility in water. The ozone composition of this invention can be stored at low temperatures (-20°C) and maintain an ozone content of over 78% for two months. In contrast, the ozone concentration of traditional ozone solutions typically drops sharply within a short period. The ozone composition provided by this invention exhibits significantly improved stability during storage, extending its effectiveness in treatment and solving the problem of easy deterioration of existing ozone solutions during storage. This makes the application of ozone compositions in tumor treatment more efficient and reliable.

[0028] To identify ozone compositions and their ozone content, this invention employs two methods: ultraviolet spectrophotometry and iodometric titration. ① Ultraviolet spectrophotometer detection method: Ozone molecules have specific ultraviolet absorption peaks, and the position of the peaks can be used to determine whether a substance contains ozone.

[0029] ② Iodometric method: This method involves the reaction of ozone with potassium iodide to generate iodine molecules. In the iodometric method, the iodine molecules can react with a standard sodium sulfite solution, and the ozone content can be calculated based on the volume of sodium sulfite consumed in the reaction.

[0030] The ozone composition provided by this invention has significant advantages in clinical application and production cost compared to existing technologies: 1. Simple and low-cost preparation process: Existing technologies often use PEG combined with other polymer materials to construct ozone compounds, which involves complex preparation processes and high raw material costs. This invention uses PEG of a specific molecular weight as a single carrier for ozonation treatment, greatly simplifying the process and significantly reducing equipment requirements and material costs for industrial production, thus exhibiting greater economic efficiency and practicality.

[0031] 2. Breakthroughs in physical properties drive innovation in drug delivery methods: Overcoming the limitations of high molecular weight: In existing technologies, when the molecular weight of PEG reaches 1000 or above, the resulting ozone composition is semi-solid or solid at room temperature. This property limits its application scenarios, allowing it to be used only as an adjunct to tumor resection surgery, by spraying or applying it to the surgical incision to prevent recurrence, and it cannot achieve deep tissue drug delivery.

[0032] (1) Precise viscosity control: Studies have found that high molecular weight polyethylene glycol (such as PEG-400 and PEG-600) has high viscosity at room temperature, and there is significant resistance when using medical syringes to aspirate and push, making it difficult to ensure the smoothness of clinical drug administration.

[0033] (2) Achieving active intratumoral therapy: The PEG-200 carrier selected in this invention maintains good liquid fluidity at room temperature and has a moderate dynamic viscosity, which can ensure smooth aspiration and precise intratumoral injection by the syringe. This improvement transforms the ozone composition from a single "postoperative adjuvant prevention" method into an active treatment method that can directly target solid tumors for in-situ ablation, greatly expanding the application scope of ozone in clinical tumor treatment.

[0034] The present invention also provides a method for preparing the ozone composition described in the above technical solution, comprising: Ozone is dissolved by passing it into a polymer containing ether bonds and / or hydroxyl groups to obtain an ozone composition.

[0035] This invention does not impose any special restrictions on the source of the raw materials; commercially available products familiar to those skilled in the art can be used.

[0036] In this invention, the ozone is preferably prepared using a PEM-based ozone electrolyzer. This invention utilizes a PEM-based ozone electrolyzer to generate ozone, which efficiently electrolyzes ultrapure water to produce ozone, which is then directly introduced into the reaction system. By adjusting the current and reaction time, the ozone concentration can be precisely controlled, avoiding the problem of unstable ozone concentration in traditional ozone generators. This not only improves the yield of the ozone composition but also significantly shortens the reaction time.

[0037] The present invention does not have any special limitation on the model of the PEM ozone electrolyzer; any instruments and equipment well known to those skilled in the art can be used.

[0038] In this invention, the ozone introduction rate is preferably 400-500 mg / h, more preferably 450 mg / h; the ozone introduction time is preferably ≥3h. This invention can adjust the ozone concentration in the ozone composition by controlling the introduction time; when the introduction time is 3h, the ozone concentration is 1 g / L; when the introduction time is 17h, the ozone concentration is 6 g / L.

[0039] In this invention, the preferred dissolution temperature is room temperature. Using room temperature (25°C) avoids the decomposition of ozone due to excessively high temperatures.

[0040] The preparation method of the present invention is simple and efficient, and can obtain a stable ozone composition in a short time, and has good operability and efficiency.

[0041] The preparation method provided by this invention uses a PEM-made ozone electrolyzer to generate ozone. The ozone composition preparation process is highly efficient and has no obvious by-products, which greatly improves the yield of the ozone composition. This efficient ozone generation capability enables this invention to obtain a high concentration of ozone composition in a short time, while ensuring the smooth progress of the preparation and the high quality of the product.

[0042] In summary, this invention demonstrates significant advantages in terms of the purity and yield of the ozone composition. These advantages stem from the combination of polyethylene glycol and PEM in the ozone electrolyzer technology, thereby enhancing the technical effectiveness of this invention and solving several problems in the prior art.

[0043] The present invention also provides the application of the ozone composition described in the above technical solution or the ozone composition prepared by the preparation method described in the above technical solution in antitumor drugs.

[0044] In this invention, the antitumor drug is preferably administered via intratumoral injection into a solid tumor. This invention does not impose a specific limit on the dosage; it can be adjusted according to the size of the tumor.

[0045] In this invention, the preferred applications include: use alone or as a sensitizer for chemotherapy, radiotherapy, immunotherapy, targeted therapy or oncolytic virus therapy.

[0046] The technical solutions of this invention will be clearly and completely described below with reference to the embodiments thereof. Obviously, the described embodiments are only a part of the embodiments of this invention, and not all of them. All other embodiments obtained by those skilled in the art based on the embodiments of this invention without creative effort are within the scope of protection of this invention.

[0047] The PEG-200 used in the examples and comparative examples is a colorless and transparent liquid with an average molecular weight of 200. It is industrial grade and commonly used in pharmaceutical, cosmetic, food and biochemical research. The ultrapure water used in the examples and comparative examples has a conductivity of less than 18.2 MΩ·cm, making it suitable for preparing high-purity chemical reagents. Source: commercially purchased laboratory-grade ultrapure water. The PEM ozone electrolyzer used in the examples is a commercially available PEM ozone electrolyzer.

[0048] Example 1 The ozone composition consists of polyethylene glycol and ozone dissolved in polyethylene glycol; The average molecular weight of the polyethylene glycol is 200, that is, the polyethylene glycol is PEG-200; The concentration of ozone in the ozone composition is 1 g / L; The ozone composition is a liquid; The ozone composition is prepared by: Connect the reaction vessel to the PEM ozone electrolyzer via pipes, ensuring all equipment connections are tight to prevent ozone leakage; Start the PEM ozone electrolyzer to generate ozone by electrolyzing ultrapure water; Adjust the current to 12A, and at room temperature (25℃), allow the generated ozone to be introduced through a pipe into a reaction flask containing PEG-200 for 3 hours. Then, turn off the power and disconnect the ozone generator from the reaction flask to obtain an ozone composition. The ozone introduction rate is 450 mg / h.

[0049] The ozone content in the ozone composition was determined using an ultraviolet spectrophotometer and iodometric titration.

[0050] Ultraviolet spectrophotometer: Used to detect the ozone content in ozone compositions. The presence and concentration of ozone are confirmed by measuring the ultraviolet absorption peak of the solution.

[0051] Iodometric titration: Used to further verify the ozone concentration in the ozone composition. Accurate ozone content data are obtained by standard iodometric titration.

[0052] The ozone composition prepared in Example 1 was stored in a sealed container at a low temperature (-20°C) to ensure the stability of the ozone. After one month of storage at low temperature, the ozone content was 90.23%, and after six months, the ozone content was 79.65%.

[0053] Example 2 The ozone composition consists of polyethylene glycol and ozone dissolved in polyethylene glycol; The average molecular weight of the polyethylene glycol is 200, that is, the polyethylene glycol is PEG-200; The concentration of ozone in the ozone composition is 6 g / L; The ozone composition is a liquid; The ozone composition is prepared by: Connect the reaction vessel to the PEM ozone electrolyzer via pipes, ensuring all equipment connections are tight to prevent ozone leakage; Start the PEM ozone electrolyzer to generate ozone by electrolyzing ultrapure water; Adjust the current to 12A, and at room temperature (25℃), allow the generated ozone to be introduced through a pipe into a reaction flask containing PEG-200 for 17 hours. Then, turn off the power and disconnect the ozone generator from the reaction flask to obtain an ozone composition. The ozone introduction rate is 450 mg / h.

[0054] The ozone composition prepared in Example 2 was placed in a sealed container and stored at low temperature (-20°C) to ensure the stability of ozone. After one month of storage at low temperature, the ozone content was 91.52%, and after six months, the ozone content was 78.35%.

[0055] Example 3 Based on Example 1, PEG-200 was modified to PEG-400, while other conditions remained unchanged.

[0056] The ozone composition prepared in Example 3 was placed in a sealed container and stored at low temperature (-20°C) to ensure the stability of ozone. After being stored at low temperature for one month, the ozone content remained at 89.62%, and after six months, the ozone content remained at 80.07%.

[0057] Comparative Example 1 PEG-200.

[0058] The ozone composition (PEG200-O3) of Example 1 and PEG-200 of Comparative Example 1 were detected using a UV spectrophotometer, and the results are as follows: Figure 1 As shown.

[0059] from Figure 1 It can be seen that the PEG200 spectrum shows absorbance near 206 nm, which originates from the terminal absorption characteristics of saturated single bonds; the PEG200-O3 spectrum shows that the absorption band gradually broadens towards longer wavelengths and extends to about 250 nm in the 200~250 nm range, exhibiting a significant red shift characteristic; this phenomenon is mainly attributed to the formation of peroxide chromophores, namely the interaction between ozone and the ether bonds in PEG200, the interaction between ozone and the hydroxyl groups in PEG200, and the formation of auxochromes such as carboxyl groups.

[0060] Comparative Example 2 An aqueous solution of ozone with an ozone concentration of 0.1 g / L.

[0061] The stability curves of the ozone composition (PEG200-O3) prepared in Example 2 and the ozone aqueous solution (H2O-O3) in Comparative Example 2 at room temperature are shown below. Figure 2 As shown.

[0062] from Figure 2It can be seen that ozone water completely decomposes in 30 minutes, and the ozone composition provided by the present invention maintains an ozone content of 93.23% after 24 hours, exhibiting superior storage stability.

[0063] The inhibitory effect of the ozone composition of the present invention on tumor growth was evaluated by the following experiments: Six groups of mice were used in the experiment, namely: ①PBS group: Completely negative control group, given PBS solution.

[0064] ②HCl 6.0 group: Dilute hydrochloric acid and PBS were mixed in proportion to adjust the pH to 6.0, and the control ozone composition was a 1 g / L solution.

[0065] ③ HCl 5.0 group: dilute hydrochloric acid and PBS were mixed in proportion to adjust the pH to 5.0, and the control ozone composition was a solution of 6 g / L.

[0066] ④PEG200 group: negative control group, given PEG200 solution.

[0067] ⑤ PEG200-O3 1g / L group: experimental group, given PEG200-O3 solution, corresponding to Example 1.

[0068] ⑥ PEG200-O3 6g / L group: experimental group, given PEG200-O3 solution, corresponding to Example 2.

[0069] Six mice (C57BL / 6 mice, male, 5 weeks old) were used in each group for a 21-day experiment. During this period, the mice's body weight, tumor size, and clinical manifestations were observed and recorded every other day. A tumor model (mouse pancreatic cancer cells panc02) was established in mice via subcutaneous tumorigenesis. The tumor volume was measured when it reached 150-200 mm². 3 At that time, the above solution was injected into the tumor, once every 2 days, for a total of 2 injections. Before each injection, the longest diameter (L) and shortest diameter (W) of the tumor were measured, and the solution was calculated according to the formula (V=L×W). 2 The tumor volume was calculated using the formula (×1 / 2), and then plotted and statistically analyzed.

[0070] Figure 3 This figure shows the gross appearance of mice injected with subcutaneous tumors in the PBS group, HCl 6.0 group, HCl 5.0 group, PEG200 group, PEG200-O3 1g / L group and PEG200-O3 6g / L group, respectively. Each group consists of 6 mice on the same day.

[0071] from Figure 3It can be seen that the tumor size of mice in the HCl 6.0 group and HCl 5.0 group was not significantly different from that in the PBS group, and tumor growth was not significantly inhibited. In contrast, the tumor proliferation rate of mice in the PEG200 group, PEG200-O3 1g / L group and PEG200-O3 6g / L group was significantly slowed down, and the tumor volume was significantly smaller than that in the PBS group at the end of the experiment.

[0072] Figure 4 The tumor volume curves before and after injection of subcutaneous tumors in mice were obtained using PBS, HCl 6.0, HCl 5.0, PEG200, PEG200-O3 1g / L, and PEG200-O3 6g / L groups, respectively.

[0073] from Figure 4 It can be seen that the tumor volume of mice in the PEG200-O31g / L group and the PEG200-O36g / L group was significantly lower than that in the PEG200 group, and there was a significant difference compared with the PBS group. In particular, the tumor volume of mice in the PEG200-O36g / L group was the smallest, showing a stronger inhibitory effect.

[0074] Figure 5 This is a scatter plot summarizing the weight of subcutaneous tumors in mice obtained from dissection after two intratumoral administrations.

[0075] The data on the weight of subcutaneous tumors obtained from dissection of mice after two intratumoral administrations are summarized in Table 1.

[0076] Table 1. Summary of subcutaneous tumor weights obtained from dissection of mice in each group after two intratumoral drug administrations.

[0077] from Figure 5 As shown in Table 1, through one-way ANOVA and subsequent Tukey's HSD test, the PEG200 group, PEG200-O3 1g / L group, and PEG200-O3 6g / L group showed statistically significant differences compared with the PBS group, HCl 6.0 group, and HCl 5.0 group (p<0.05); the inhibitory effect of the ozone composition was more significant at a concentration of 6g / L.

[0078] The results of this experiment show that the ozone composition of the present invention exhibits a strong anti-tumor effect in the PEG system, and the anti-tumor effect gradually increases with the increase of the ozone composition concentration. Tumor growth in mice in the PEG200-O3 6g / L group was significantly inhibited, and the tumor weight and volume were significantly reduced, demonstrating the potential of this ozone composition in tumor treatment.

[0079] In summary, the advantages of the ozone composition provided by this invention are as follows: ① Highly efficient ozone concentration generation rate: This ozone composition utilizes a PEG system, enabling the achievement of high ozone concentrations in a very short time. Specifically, the ozone concentration can be increased to 1 g / L within 3 hours, and to 6 g / L within 17 hours. This highly efficient ozone generation capability allows the compound to rapidly provide the required ozone dose during treatment, thereby improving therapeutic efficacy.

[0080] ② Excellent stability: This ozone composition exhibits excellent stability and can be stored for extended periods at low temperatures. When stored at -20°C, the ozone content maintains up to 90% stability within one month, with almost no significant decay. This provides convenience for practical applications, avoiding dosage inaccuracies caused by ozone volatilization or degradation, and ensuring the stability of ozone content and therapeutic efficacy with each use.

[0081] The advantage of this ozone composition is that it can not only generate high concentrations of ozone rapidly, but also maintain stability for a long time, making it ideal for clinical or experimental applications such as cancer treatment.

[0082] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. An ozone composition comprising a polymer containing ether bonds and / or hydroxyl groups and ozone dissolved in said polymer.

2. The ozone composition according to claim 1, characterized in that, The concentration of ozone in the ozone composition is 0.1~200g / L.

3. The ozone composition according to claim 1, characterized in that, The ozone composition may be in the form of a liquid, a semi-solid, or a solid.

4. A method for preparing the ozone composition according to any one of claims 1 to 3, comprising: Ozone is dissolved by passing it into a polymer containing ether bonds and / or hydroxyl groups to obtain an ozone composition.

5. The use of the ozone composition according to any one of claims 1 to 3 or the ozone composition prepared by the preparation method according to claim 4 in antitumor drugs, anti-infective drugs or immunomodulators.

6. The application according to claim 5, characterized in that, The applications include: use alone or as a sensitizer for chemotherapy, radiotherapy, immunotherapy, targeted therapy or oncolytic virus therapy.

Images